Company Profile

Plex Pharmaceuticals Inc (AKA: CalAsia Pharmaceuticals Inc)
Profile last edited on: 10/14/20      CAGE: 5Q2T2      UEI: U6KWJVLD1NU5

Business Identifier: Drug discovery for diseases caused by protein misfolding
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6330 Nancy Ridge Drive Suite 102
San Diego, CA 92121
   (858) 587-8800
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Plex (Latin for fold) Pharmaceuticals - formerly dba CalAsia Pharmaceuticals - is an early-stage biotechnology company focused on drug discovery involving diseases caused by protein misfolding: ALS, Parkinson’s disease and cataracts. Plex was originally organized around acceleration seminal academic discoveries into safe and effective treatments for unmet and under-served medical needs with a focus on neurodegenerative disorders. With funding from the Michael J.Fox Foundation to support its efforts in fragment-based screening and structure-based drug design, Plex’s ALS effort structured around the work of Yale University School of Medicine's Dr. Arthur Horwich - one of the co-discoverers of the protein chaperone machinery, for which he received a Lasker Award. With NIH support, Plex Pharmaceuticals also worked on a development program for Dengue, West Nile and Zika antiviral drugs and worked on a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for glioblastoma. Focused on the rapid discovery of drug-like small molecules, Plex's core technology platform effectively combines functional fragment screening with X-ray crystallography co-crystallization guided by a streamlined structure-based design approach to design and synthesize New Chemical Entities (NCEs) with drug-like properties. For closely related target isotypes, Plex employs a differential fragment screening method as a powerful tool to identify highly isotype-selective and pan inhibitors to improve therapeutic efficacy. In August 2017, the firm was acquired by Collidon for an undisclosed amount but remains SBIR eligible. Under the deal, Collidion delivers management and operational support to boost Plex Pharmaceuticals’ drug discovery prog

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Hojabr Alimi -- Chairman & CEO

  Duncan McRee -- Co-Founder and Former CEO

  Allan Rubenstein -- Chairman

  David F Carney -- Senior Scientist

  Carol A Pad Feghali-Bostwick

  Sameer Harish -- Director of Finance

  Prashant Mehta -- Director Business Development

  Sridhar G Prasad -- CSO and Co-Founder

  Santosh C Sinha

  William H Watson III -- Vice-President of Global Sales and Business Development

  Theresa M Williams -- Executive Consultant, Chemistry